Index
Module 11 • Cardiology
Cardiovascular Critical Care I
84%
Data Tables
Cardiovascular Critical Care I
Sajni V. Patel ~2 min read Module 11 of 20
57
/ 68

Cardiovascular Critical Care I

ii.

Antibiotic treatment

(a)Antibiotic coverage should account for site of suspected infection, previous pathogens

and susceptibilities, proximity to driveline site or VAD pocket, and any other potential

exposure or bacteremia secondary to the procedure. Prophylactic antibiotic coverage

for VAD-related or non–VAD-related surgical procedures should account for site of

procedure, previous infections, proximity to driveline site or VAD pocket, and any other

potential exposure or bacteremia secondary to the procedure. In some circumstances,

this requires broader prophylactic antibiotic coverage (Interact Cardiovasc Thorac Surg

2012;14:209-14).

(b)Treatment duration depends largely on the type of infection. However, if the infection is

VAD related or VAD specific, prolonged antimicrobial therapy (more than 4 weeks) is

commonly used.

(c)Because LVAD exchange is not without considerable risk, long-term oral antibiotic

suppression therapy may be considered for some infections.

Patient Case (Continued)

8

J.M. is no longer in AF but remains in cardiogenic shock. The cardiac intensive care unit team has consulted

the cardiothoracic surgeons for evaluation of his mitral valve disease and has considered advanced HF

therapies. In the patient’s decompensated state, he would likely need additional optimization if he were to

undergo surgery. Which temporary means of mechanical circulatory support (MCS) might be most favorable

to help stabilize this patient’s cardiogenic shock in the setting of moderate to severe mitral regurgitation?

A.Venoarterial extracorporeal membrane oxygenation (ECMO)
B.Venovenous ECMO
C.Intra-aortic balloon counterpulsation
D.None; the patient likely requires urgent surgery.
D.Heart Transplantation (J Heart Lung Transplant. 2024;43(10):1529-1628.e54)
1

Transplantation remains the gold-standard treatment for end-stage HF.

2Many variables limit the utility of heart transplantation, foremost of which is donor availability and

donor-recipient tissue compatibility.

3

Other limitations may include recipient characteristics of:

Mental health

Social support

Adherence to medication and appointments

d.Severe pulmonary hypertension

Cancer

Infection

Tobacco or ethanol use

Illicit drug use

4

Additional considerations associated with thoracic transplantation in the ICU, such as immunosuppression,

rejection, and other complications, are beyond the scope of this review.

HD Video Explanation — Synchronized with PDF
Starts at: minute 56 Open on YouTube